Details of the Drug Combination

General Information of Drug Combination (ID: DC71T6Y)

• Drug Combination Name: Immune globulin + CJC-1295
• Indication: Alzheimer disease; Status: Phase 1 [1]
• Component Drugs:
  Immune globulin (DMX2OMJ): N.A.
  CJC-1295 (DMLACBI): Small molecular drug

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Clinical pipeline report, company report or official report of Octapharma.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] ClinicalTrials.gov (NCT00110708) Safety and Efficacy Study in the Treatment of Intestinal Problems Associated With Autism. U.S. National Institutes of Health.
• [6] ClinicalTrials.gov (NCT00448253) Safety and Pharmacokinetic Study of Anthrax Immune Globulin Derived From Human Serum. U.S. National Institutes of Health.
• [7] ClinicalTrials.gov (NCT00267527) A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity. U.S. National Institutes of Health.